Pharmaceuticals News and Research

RSS

CMS issues J-code for Savient's KRYSTEXXA

Savient Pharmaceuticals, Inc. announced that the Centers for Medicare and Medicaid Services has assigned a product-specific billing code, or J-code, for KRYSTEXXA (pegloticase), which is used for the treatment of chronic gout in adult patients refractory to conventional therapy.

3 Nov 2011

Columbia Laboratories third quarter total net revenues decrease to $4.9 million

Columbia Laboratories, Inc. today reported financial results for the three- and nine-month periods ended September 30, 2011.

3 Nov 2011

Allos third quarter net loss decreases to $11.2 million

Allos Therapeutics, Inc. today reported financial results for the three months ended September 30, 2011.

3 Nov 2011

ARIAD reports net income of $13.9 million for third quarter 2011

ARIAD Pharmaceuticals, Inc. today reported financial results for the third quarter of 2011 and provided an update on its corporate developments.

3 Nov 2011

Positive results from Clinuvel's US Phase II study of photoprotective drug, afamelanotide

Clinuvel Pharmaceuticals Limited, a global biopharmaceutical company with unique expertise on the interaction of light and human skin, today announced positive results of its first US Phase II study of the novel photoprotective drug afamelanotide, known as SCENESSE.

3 Nov 2011

Elsevier's 2012 eBook Frontlist collections available on SciVerse ScienceDirect

Elsevier, the world-leading publisher of scientific, technical and medical information products and services, announced today that its 2012 eBook Frontlist collections are available for advance purchase on SciVerse ScienceDirect, Elsevier's online platform for scientific content.

3 Nov 2011

Abbott to highlight latest research findings on HUMIRA at ACR annual meeting

Abbott scientists and independent researchers will highlight the latest research findings on HUMIRA (adalimumab) at this year's American College of Rheumatology (ACR) Annual Scientific Meeting, scheduled for November 5-9 in Chicago.

3 Nov 2011

State Medicaid Directors seek to sway feds on eligibility rules

In a letter to the Centers for Medicare and Medicaid Services, the state officials made recommendations about new regulations and asked for coordination between federal and state leaders. Meanwhile, in other Medicaid news, a New York doctor gets a big payout from his whistleblower lawsuit, and the Lousiania program reports a shortfall.

3 Nov 2011

Ivacaftor drug improves lung function in people with cystic fibrosis

A new study has confirmed that the drug, ivacaftor (VX-770), significantly improves lung function in some people with cystic fibrosis (CF). The results of the phase III clinical trial study, "A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation," led by Bonnie W. Ramsey, MD of Seattle Children's Research Institute and the University of Washington, were published today in the New England Journal of Medicine.

3 Nov 2011

Final results from Medivir's TMC435 phase IIb study on genotype-1 hepatitis C

Medivir AB, a research-based speciality pharmaceutical company focused on infectious diseases, today announces final results from the ASPIRE study.

3 Nov 2011

FDA approves Endo Pharmaceuticals' Felodipine Extended-release Tablets

Endo Pharmaceuticals today announced that the U.S. Food and Drug Administration has approved Felodipine Extended-release Tablets USP, 2.5mg, 5mg and 10mg.

3 Nov 2011

Isis commences ISIS-GCGRRx and ISIS-GCCRRx Phase 1 studies for type 2 diabetes

Isis Pharmaceuticals, Inc. announced today that it has initiated Phase 1 clinical studies for ISIS-GCGRRx and ISIS-GCCRRx, antisense drugs Isis is developing for the treatment of type 2 diabetes.

2 Nov 2011

AVEO third quarter net loss increases to $23.8 million

AVEO Pharmaceuticals, Inc. today reported consolidated financial results for the third quarter of 2011 and provided an update on the tivozanib clinical program.

2 Nov 2011

NIH-funded project to discover biomarkers for type 2 diabetes

Arizona State University will lead a four-year, $5 million expanded initiative sponsored by the National Institutes of Health to discover proteins, or biomarkers, to help predict cardiovascular disease and to assess potential new treatments in people with type 2 diabetes.

2 Nov 2011

Researchers identify small-molecule drug candidates for many metabolic conditions

A new discovery by Californian scientists may lead to a pharmaceutical breakthrough for a wide range of illnesses that involve the hydration of cells that line the inner surfaces of our body's organs and tissues. In a new report appearing in the FASEB Journal, the researchers describe how they used high-throughput screening to identify small-molecule drug candidates which help cells bypass defective channels that normally move salt and water through cell membranes.

2 Nov 2011

State roundup: Ga., Minn. move slowly on exchanges

The entire Massachusetts congressional delegation is asking CMS to preserve the level of safety net funding and provider payments as the state tries to renew its Medicaid waiver. "We are concerned that changes proposed by CMS could significantly threaten payments to Massachusetts health care providers providing care for the most vulnerable populations," Sens. John Kerry and Scott Brown and the 10 House members in the state's delegation wrote.

2 Nov 2011

Obama takes action to address drug shortages

President Barack Obama issued an executive order Monday directing the Food and Drug Administration to, among other steps, speed up reviews of manufacturers' applications to begin or alter production of a drug in potentially short supply.

2 Nov 2011

Targeted antibiotic safe and effective for irritable bowel syndrome

Among the most commonly used treatments for irritable bowel syndrome - which affects as many as 20 percent of the United States population - a targeted antibiotic was shown to be the safest in a new study by Cedars-Sinai researchers, based on an analysis of 26 large-scale clinical trials.

2 Nov 2011

Teva third quarter net sales increase 2% to $4.34 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended September 30, 2011.

2 Nov 2011

SurModics to sell Pharma assets to Evonik for $30 million

SurModics, Inc., a leading provider of surface modification technologies to the healthcare industry, announced today that it has entered into a definitive agreement to sell its SurModics Pharmaceuticals assets to Evonik Industries AG for $30 million in cash.

2 Nov 2011